To provide the information your oncologist is not telling you or doesn't have the time to!
Dive into the heart of innovation with our “Clinical Trials” subcategory, where we unveil the dynamic world of oncology research in real-time. Discover the latest developments and breakthroughs in cancer treatment as we explore ongoing clinical trials and their potential impact on patient care. Gain insights into the rigorous process of testing novel therapies, uncover promising treatment options, and learn how these trials contribute to advancing the field of oncology. Stay informed and be part of the journey towards more effective and compassionate cancer care.
Three-year NADINA data showed something that shouldn’t happen: near-complete responders did substantially worse than partial responders — 62.3% versus 87.5% recurrence-free survival. One design feature separates NADINA from every neoadjuvant melanoma trial before it. NADINA mandated full lymph node dissection in every patient; PRADO left the basin alone in major responders. I think that may be the explanation, and nobody raised it.
Four randomized trials and one excellent symposium defined day one of the melanoma program at ESMO 2026 in Madrid: an oral HDAC inhibitor added to nivolumab, a BRAF/MEK-plus-immunotherapy triplet, two trials pushing TIL cell therapy earlier and lighter, and a landscape in metastatic uveal melanoma that has changed faster than most providers realize. Here is the data as presented, and my take on each.
OBX-115 engineered TIL therapy achieved a 67% response rate in melanoma patients who failed immunotherapy — with no IL-2 and outpatient-friendly dosing.
Protecting vision, preserving the person — the promise of ocular-sparing oncology.
Details once dismissed as trivial—like timing—can quietly reshape cancer care.
Sometimes restraint is the wiser choice — half of patients are cured with PD-1 alone.
When innovation meets immune activation, new possibilities emerge for melanoma care.
Targeting PRAME with TCR-T cell therapy may mark a new era for immunotherapy in melanoma and beyond.
When immune therapy clears cancer, the real question for resectable tumors becomes: Do we still need to resect?
From early-stage to brain metastases, ASCO’s latest melanoma abstracts spotlight the growing power of targeted and immune-based therapies across disease stages.